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Abstract
Background: The voltage gated potassium (K+) channels Eag and HERG have been implicated in the pathogenesis
of various cancers, through association with cell cycle changes and programmed cell death. The role of these
channels in the onset and progression of ovarian cancer is unknown. An understanding of mechanism by which
Eag and HERG channels affect cell proliferation in ovarian cancer cells is required and therefore we investigated
their role in cell proliferation and their effect on the cell cycle and apoptosis of ovarian cancer cells.
Methods: The presence of Eag and HERG was determined in SK-OV-3 cells using immunofluorescence and
western blotting. The effect of the Eag blockers (imipramine and clofilium) and HERG blockers (E-4031 and
ergtoxin) on cell proliferation was assessed using the MTS assay with further investigation of their role in the cell
cycle and apoptosis determined by flow cytometry.
Results: Eag and HERG channels were present in the cytoplasm and nuclei of SK-OV-3 cells. There was significant
inhibition of proliferation of SK-OV-3 cells by imipramine (P < 0.001) and ergtoxin (P < 0.05) at 72 hours of culture.
Incubation of cells with ergtoxin led to the accumulation of cells in the S and G2/M phase, while cells
accumulated in S phase after incubation with E-4031, with no effect on apoptosis. Imipramine did not affect the
cell cycle but increased the proportion of SK-OV-3 cells undergoing early apoptosis.
Conclusion: Both Eag and HERG channels are expressed in SK-OV-3 ovarian cancer cells and have a role in cell
proliferation. HERG channels affect the cell cycle while Eag channels are implicated in the inhibition of apoptosis of
ovarian cancer cells. The family of Eag channels may represent a new therapeutic target for the treatment of
ovarian cancer.
Introduction
Voltage gated potassium (K+) channels have been shown
to be expressed in various cancers and appear to play an
important role in progression of cells through the cell
cycle, in part, due to the ion translocation across the
plasma membrane [1].
The Ether-a-go-go (Eag) gene and Human Eag Related
Gene (HERG) encode voltage gated K+ channels belong-
ing to the Ether-a-go-go family [2]. The Eag channel is
aberrantly expressed in various cancers and has been
shown to have oncogenic potential in heterologous sys-
tems [3]. Eag channels also affect the transition of
cancer cells through the cell cycle [4]. Unlike Eag chan-
nels that are abundant in the central nervous system,
HERG channels have been long known to play an
important role in the repolarisation of the heart and are
implicated in the molecular basis of familial Long QT2
syndrome [5]. HERG channels also play an important
role in regulation of the cell cycle in various tumours
[6]. Interestingly, a role for voltage gated K+ channels in
proliferation of ovarian cancer cells has been proposed
following inhibition of proliferation with the non speci-
fic voltage gated blocker 4-aminopyridine (4-AP) that
led to accumulation of cells in the G1 phase [7].
Ovarian cancer is the second most common female
genital malignancy in the UK, accounting for 6% of
female deaths due to cancer. Worldwide there are about
225,000 new cases of ovarian cancer of which 125,000
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women die each year. The highest incidence of the dis-
ease is in Northern Europe and USA and the lowest in
Africa and Asia [8]. Despite advances in chemotherapy,
ovarian cancer mortality rates in the UK since the early
1970s, have remained stable at ~10- 12 per 100,000
women. This is in part due to the asymptomatic nature
of the disease with most women presenting at a late
stage [8]. Hence, there remains a need for the develop-
ment of newer therapies based on new targets to
improve survival. Given their association with various
cancers, both Eag and HERG channels show promise as
future therapeutic targets.
We have shown that Eag and HERG channels are
expressed in SK-OV-3 ovarian cancer cells and their
blockers significantly inhibit their proliferation. HERG
blockers inhibit the proliferation at S and G2/M phase
while Eag blocker impramine increases early apoptosis
in ovarian cancer cells with no effect on cell cycle.
Material and methods
Cell line
The SK-OV-3 cell line (Passage 13) was kindly donated
by Dr Dimitra Dafou, Translational Research Labora-
tories, University College Hospital, London in February
2009, from an authenticated stock provided by the
American Type Culture Collection (ATCC). Cell cul-
tures were grown in Roswell Park Memorial Institute
(RPMI) 1640 medium supplemented with 10% fetal
bovine serum (FBS) and antibiotics (100 u/ml penicillin
and 100 μg/ml streptomycin; Invitrogen, Paisley UK).
Antibodies and Drugs
Mouse anti-human Eag antibody was purchased from
Abnova Labs (Taiwan). Rabbit anti-human HERG anti-
body was from Abcam laboratories (UK) while secondary
anti-mouse and anti-rabbit fluorescein isothiocyanate
(FITC) conjugated antibodies were obtained from Sigma
(Poole UK). Imipramine and clofilium were obtained
from Sigma Aldrich UK while E-4031 and ergtoxin were
from Caltag Medsystems, UK.
Immunofluorescence
The SK-OV-3 cells were grown on cover slips in 24 well
plates and incubated for 24 hours until 80% confluent.
Cells were then fixed with 4% paraformaldehyde for
20 min and treated with 0.5% Igepal before blocking
with 3% BSA/5% glycine in phosphate buffered saline
(PBS) followed by 10% goat serum in PBS. Eag and
HERG (both 1:100 in 10% goat serum/PBS) antibodies
were added to the wells for overnight incubation at 4°C.
Wells containing 10% goat serum without the primary
antibody were used as a negative control. After incuba-
tion, FITC conjugated secondary antibody (1:50) in 10%
goat serum/PBS was added and cells incubated at room
temperature for 90 min. Images of the cells were viewed
on a fluorescence microscope (Axiovert, Zeiss) and cap-
tured using Cell F software (Olympus UK).
Western blotting
The SK-OV-3 cells were initially washed three times
with Hanks balanced salt solution (HBSS) before collec-
tion by scraping and lysis in homogenisation buffer
[320 hM sucrose, 10 mM Tris base (pH 7.8), 50 mM
potassium chloride, 1 mM EDTA, 0.5% Igepal, 1:500
protease inhibitor cocktail and 1:100 phosphatase inhibi-
tor cocktail II (Sigma Aldrich)] at room temperature.
A crude cell lysate was obtained by centrifugation at
14,000 g for 60 min at 4 °C twice. Protein concentration
was determined by the Bicinchoninic acid method with
bovine serum albumin (BSA) as a standard. The protein
samples (50 μg) were separated on 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and then
transferred to a nitrocellulose membrane. After being
blocked in 10% milk protein (Marvel) in TBS-T (20 mM
Tris, pH7.4, 500 mM NaCl, 0.01% Tween 20), the mem-
brane was incubated overnight at 4 °C with Eag (1:100)
and HERG antibodies (1:1000). The membrane was then
washed six times with TBS-T for 10 min each and incu-
bated with secondary antibody linked to alkaline phos-
phatase (Eag 1:1000 and HERG 1:1500, Sigma-Aldrich)
for 90 minutes at room temperature. After washing six
times with TBS-T again for 10 minute each, the blot
was then developed using alkaline phosphatase substrate
enhancer. Blots were viewed using the chemidoc ima-
ging system (Bio Rad Labs).
Cell proliferation assays
The effect of the Eag blockers (imipramine and clofilium)
and HERG blockers (E-4031 and ergtoxin) on SK-OV-3
cells, was examined using MTS (3-(4, 5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt) assay in the form of the CellTiter
96 aqueous non-radioactive cell proliferation assay kit
(Promega, UK). The assay was performed according to
the manufacturer’s instructions. Briefly, SK-OV-3 cells
were seeded at a density of 5000 cells/100 μl in RPMI
1640 medium containing 10% FBS in triplicate wells of a
96 well plate (Perkin Life Sciences) and incubated for
24 hours in 5% CO2/air at 37°C. Thereafter, the medium
was aspirated and replaced with 100 μl fresh medium
containing Eag and HERG blockers at various concentra-
tions or medium only which served as a negative control.
All drugs were reconstituted in RPMI 1640. Cells were
incubated for 96 hours in the test drug and proliferation
assessed daily by the addition of MTS reagent. After an
hour’s incubation, the plates were read at 490 nM using a
Victor 1427 multilabel counter (Wallac). All assays were
repeated thrice. The choice of drug concentrations used
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in the cell proliferation was based on previous published
data for imipramine [9], clofilium [10], E-4031 [11] and
ergtoxin [12].
Cell cycle assay
SK-OV-3 cells were seeded at a density of105/ml of
RPMI 1640 with 10% FBS in a 6 well plate and incu-
bated for 24 hours in 5% CO2/air at 37°C. The medium
was aspirated after 24 hours and replaced with fresh
medium in the presence and absence of Eag blockers
(imipramine 50 μM and clofilium 3300 nM) and HERG
blockers (E-4031 20 μM and ergtoxin 100 nM). The
plate was then incubated for 48 hours. 1 × 105/ml cells
were dispensed in FACS tubes, washed with PBS and
fixed with 70% ethanol. 10 μl/ml of 10 mg/ml RNase
solution (DNase free, Sigma-Aldrich?) was added and
then cells stained with 50 μl/ml of propidium iodide
(1 mg/ml, Sigma). Cells were incubated at 37°C for
20 min and fluorescence from 20,000 events determined
using a Coulter Altra Flow cytometer. The population of
cells in the G0/G1, S and G2/M phases were quantitated
based on scatter analysis using WinMDI 2.9 and
Cylchred software. The highest inhibitory concentrations
of all drugs in cell proliferation experiments were used
for cell cycle analysis and apoptosis assay.
Apoptosis assay
Apoptosis was assessed using Annexin V binding with
propidium iodide (PI) staining using the TACS Annexin
V kit (Trevigen Inc). SK-OV-3 cells were initially seeded
at concentration of 100,000 cells/ml, in 6 well plates
and incubated at 37°C in a humidified atmosphere with
5% CO2/air. After 24 hours, the Eag blockers (imipra-
mine 50 μM and clofilium 3300 nM) and HERG block-
ers (E-4031 20 μM and ergtoxin 100 nM) were added
with one well containing medium only serving as a con-
trol. After exposure to the drugs for 48 hours, cells were
dissociated using 0.05% trypsin/EDTA and then washed
with cold PBS. approximately 100,000 cells were then
suspended in 100 μl of Annexin V Incubation buffer
containing 10 μl of 10 × binding buffer (100 mM Hepes,
pH 7.4, 1.5 M NaCl, 50 mM KCl, 10 mM MgCl2 and 18
mM CaCl2), 10 μl of PI (50 μg/ml), 1 μl Annexin-FITC
in deionised, distilled water. After incubation in the
dark for 15 minutes at room temperature, binding buffer
was added and cellular fluorescence analysed by the
Coulter Altra Flow cytometer for 10,000 events. Control
tubes containing binding buffer only and cells contain-
ing Annexin V alone and PI alone were initially used to
calibrate the instrument.
Statistical analysis
Statistical significance was determined using one way
analysis of variance (ANOVA) with Dunnet’s multiple
comparison post hoc analysis (Graphpad Prism 5). All
results are presented as mean ± standard error of mean
(SEM), with data considered significant at P < 0.05.
Results
1. Eag and HERG channels are expressed in ovarian
cancer cells
SK-OV-3 cells demonstrated positive immunofluores-
cence in the cytoplasm and the nucleus for both Eag
and HERG channels as shown in Figure 1 (A and B).
No immunoreactivity was observed in negative control
experiments where primary antibody was replaced with
goat serum, (Figure 1C). Eag and HERG protein expres-
sion in SK-OV-3 cells was alsodemonstrated by Western
blotting (Figure 1D).
2. The proliferation of SK-OV-3 cells is significantly
inhibited by both Eag and HERG blockers
The Eag blocker imipramine at 50 μM significantly inhib-
ited the proliferation of SK-OV-3 cell lines at 72 hours of
culture (P < 0.001; Figure 2A) while clofilium (100-3300
nM) did not show any effect on proliferation at any of
the time points tested ( Figure 2B). Ergtoxin significantly
inhibited the proliferation of SK-OV-3 cells at 33 (P <
0.01) and 100 hM P < .05) ( Figure 2C) while no signifi-
cant effect of E-4031 on cell proliferation at any of the
concentrations applied, was observed ( Figure 2D). All
experiments were repeated thrice.
3. E-4031 and Ergtoxin inhibit proliferation through their
action on the cell cycle
To elucidate the effect of these drugs on the cell cycle,
we investigated the effect of Eag and HERG blockers on
SK-OV-3 cells using flow cytometry. Both Eag blockers
imipramine 50 μM and clofilum 3300 hM demonstrated
no effect on the G0/G1, S or G2M phases of the cell
cycle (Figure 3A-C). E-4031 (20 μM) led to accumula-
tion of cells in the S phase of the cell cycle (Figure 3B),
while ergtoxin (100 hM) a Centruroides noxius scorpion
toxin, a known specific HERG channel blocker [13]
increased accumulation of cells in S (Figure 3B) and
G2/M phases (Figure 3C). The analysis of percentage of
cells in various phases was done using Cylchred software
4. Imipramine affects the proliferation of SK-OV-3 cells
through apoptosis
Annexin V binding assay was used as it has been shown
to be a good indicator for detection of cells that are pro-
grammed to undergo early apoptosis [14].Only cells
treated with 50 μM imipramine underwent early apopto-
sis compared to control, as determined by Annexin V
binding while 3300 hM clofilium, 20 μM E-4031 and
100hM ergtoxin had no effect on apoptosis (Figure 4A
and 4B).
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Figure 2 Effect of Eag and HERG blockers on SK-OV-3 cell proliferation. There was a significant inhibition of proliferation of SK-OV-3 cells
on incubation with the Eag blocker imipramine at a concentration of 50 μM (A) and the HERG blocker ergtoxin (100hM) (Figure 2C) (* P < 0.05,
**P < 0.01, ***P < 0.001).
Figure 1 Presence of Eag and HERG channels on SK-OV-3 cells. Ovarian cancer cells demonstrate immunofluorescence staining
predominantly in the nucleus and cytoplasm with both (A) Eag and (B) HERG antibodies (C) negative control where primary antibody is
replaced with goat serum showing no immunofluorescence (D) Eag and HERG protein demonstrated by SK-OV-3 cells on western blotting.
Neuroblastoma (SHSHY) and colon cancer (Caco3) cells lines were used as positive control for Eag and HERG respectively.
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Figure 4 Effect of Eag and HERG blockers on apoptosis of SK-OV-3 cell line. Cells treated with imipramine (50 μM) showed significantly
high number of cells programmed to undergo apoptosis compared to control cells (*P < 0.05), while clofilium (3300hM), E-4031 (20 μM) and
ergtoxin (100hM) showed no effect on apoptosis.
Figure 3 Cell cycle analysis after incubation with Eag and HERG blockers. Effect of Eag blockers (imipramine and clofilium) and HERG
blockers (E-4031 and ergtoxin) on SK-OV-3 cells. E-4031 (20 μM) shows a block after S phase leading to increased cells in the S phase (Figure 3B)
while ergtoxin (100hM) has an effect on G2/M cell cycle checkpoint leading to the accumulation of cells in G2/M and S phase and less cells
going through to G1 phase (Figure 3A-C) (* P < 0.05, ** P < 0.01). Imipramine (50 μM) and clofilium (3300hM) showed no effect on cell cycle.
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Discussion
Eag and HERG channels are known to be associated
with cell proliferation and cell cycle in various cancers
[1,4]. Both of these channels belong to the same ether-
a-go-go family and share a similar structure therefore
any drug inhibiting Eag will potentially also affect HERG
channels leading to undesirable cardiac side effects [15].
Imipramine has shown Eag blocking activity in HEK293
cells expressing Eag channels [9], while clofilium has
been shown to block both Eag and HERG channels but
is not considered HERG specific [10]. E-4031 has also
been shown to inhibit HERG channels [16] while erg-
toxin is a specific HERG blocker [13].
In our study, SK-OV-3 cells exhibited immunofluores-
cence for both anti-Eag and anti-HERG antibody.
Immunostaining was localised to nuclei and cytoplasm
providing support for the presence of these channels in
ovarian cancer. Western blotting confirmed expression
of both Eag and HERG in SK-OV3 cells. The exact
function of Eag and HERG channels in the cytoplasm
and nucleus is not known although its cytoplasmic
expression may suggest retention due to impaired traf-
ficking of this protein. Imipramine has been shown to
inhibit various channels at IC50 values that range
between 1- 30 μM [9], although we found that a higher
concentration of imipramine (50 μM) was needed to
demonstrate significant inhibition of proliferation of
ovarian cancer cells compared with effects on whole-cell
Eag currents [9]. Clofilium has been shown to block Eag
channels expressed in Xenopus oocytes and HEK cells
[10] but has not tested in cancer cells.
The lack of inhibition of proliferation of SK-OV-3 cells
observed with E-4031, is in line with findings in breast
cancer cells [11]. However, many other cancers that
express HERG channels such as leukaemia [17] and color-
ectal cancer [18] have shown inhibition with E-4031. Erg-
toxin due to its specificity of blockade of HERG channels
significantly inhibited ovarian cancer cells. In contrast, erg-
toxin did not affect breast cancer cell proliferation even at
concentrations of 300 hM [11]. Various mechanisms have
been postulated to explain the effect of voltage gated K+
channels on cell proliferation. The most accepted explana-
tion suggested is through their effects on cell volume and
membrane potential [19]).
In order to investigate if the anti proliferative effects
of Eag and HERG channels were cell-cycle specific, we
incubated the cells with the drugs in their highest inhi-
bitory concentrations as tested in proliferation assays
and carried out cell-cycle phase distribution analysis by
flow cytometry. Neither imipramine nor clofilium had
any demonstrable effects on the cell cycle although imi-
pramine is associated with accumulation of cells in G0/1
phase in melanoma [20]. The effect of E-4031 showing
accumulation of cells in S phase is in contrast to the
effects of this drug in leukaemia and melanoma cells
where it inhibited G1/S transition [17,20]
We have also shown that imipramine inhibits SK-OV-
3 proliferation by inducing early apoptosis with no effect
on cell cycle while clofilium, E-4031 and ergtoxin had
no effect on apoptosis of SK-OV3 cells. Imipramine has
been shown to induce apoptosis of melanoma cells at
concentrations greater than 20 μM [20], but no effect
on apoptosis was noted on neuroblastoma cells at
50 μM [21]. Clofilium has been shown to induce apop-
tosis in human promyelocytic leukaemia [22] but was
used at a higher concentration (10 μM), than that used
for our experiments. This may explain the lack of effect
of clofilium on apoptosis in our system. E-4031 has
shown no effect on apoptosis on leukaemic cells [17]
which is consistent with our results.
Our results demonstrate that Eag and HERG block-
ers exert their antiproliferative effects through different
mechanisms. The effects of imipramine on prolifera-
tion, though not cell-cycle specific, appeared to be
through induction of early apoptosis via blockade of
Eag channels while ergtoxin showed no effect on apop-
tosis but exhibited its antiproliferative actions by
blocking cells in the G2/M phase. There are no speci-
fic blockers of Eag and HERG channels and both Eag
and HERG blockers have cross reactivity with other K+
channels [19]. The drugs used in our experiments have
been shown to block specifically Eag and HERG chan-
nels in heterologous systems but there is a possibility
that they may act via a different unidentified mechan-
ism. Our inference from the experiments is the most
plausible interpretation of findings given the available
evidence. Although further detailed analysis of
mechanisms underlying the effect of channel blockers
in ovarian cancer is needed, the significance of target-
ing channels that determine key features such as cell
size and membrane potential as they progress through
the cell cycle offers new opportunities through which
to manipulate proliferation and apoptosis. Indeed car-
boplatin, a chemotherapeutic agent is routinely used to
treat ovarian cancer acts by inhibiting DNA synthesis
and promoting apoptosis of cancer cells [23]. It is con-
ceivable that drugs targeting the Eag channel family
may potentially be combined with carboplatin and
used in patients with recurrence to reduce the dosage
of carboplatin and improve survival.
In conclusion, we have shown that Eag and HERG chan-
nels are present in SK-OV-3 ovarian cancer cells and have
a role in their cell proliferation. Imipramine and ergtoxin
affect proliferation by different pathways and have a
potential therapeutic role in the treatment of patients with
ovarian cancer.
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